Blood Test Detects 90% of Stage 0-I Pancreatic Cancer Cases
A Kanazawa University study found that a blood-based gene expression test detected 90% of early-stage pancreatic cancer cases, outperforming CA19-9, which identified only 10%.
Category: Pancreatic
Pancreatic
Latest
Pancreatic
Latest
KRAS ctDNA Is Predictor of Metastasis and Survival in Pancreatic Cancer
A Mayo Clinic study found that detecting KRAS ctDNA in pancreatic cancer patients signals a higher risk of cancer spread and poorer survival.
Pancreatic
Latest
Pancreatic Cancer Early-Detection Test Gets Positive Clinical Validation
Immunovia's CLARITI study validated its next-generation test for early-stage pancreatic cancer, achieving 78% sensitivity and 94% specificity.
Pancreatic Cancer Test May Boost IVD’s Role in Early Disease Detection
Immunovia’s new pancreatic cancer test demonstrated a specificity of 98% and a sensitivity of 75% for early-stage 1 and 2 pancreatic cancers.
Read More
Groundbreaking New Blood Test Offers Early Pancreatic Cancer Diagnosis
Researchers applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism.
Read More
Immunovia Completes Discovery Phase for Next-Gen Pancreatic Cancer Test
Immunovia, a company focused on pancreatic cancer detection, successfully completed of the discovery phase of its next-generation test.Â
Read More
Pancreatic Cancer Test Gets CPT Code, Preliminary Payment Determination from the CMS
The AMA issued a new Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for the Avantect Pancreatic Cancer Test.Â
Read More
NCI Grant to Improve Early Detection of Pancreatic Cancer
Amplified Sciences will use the grant money to develop a test to determine if pancreatic cysts are benign or potentially malignant.
Read More
Artificial Intelligence Predicts Future Pancreatic Cancer
An artificial intelligence tool has successfully identified those at the highest risk for pancreatic cancer up to 3 years before diagnosis.
Read More
PDACatch an FDA Breakthrough Device for Pancreatic Cancer Detection
Singlera Genomics’ PDACatch assay is a novel DNA methylation-based liquid biopsy assay for the detection of pancreatic adenocarcinoma in individuals at high risk for the disease.
Read More
Biomarkers Show Promise for Finding Pancreatic Cancer Risk Early
A research team identified biomarkers that could help distinguish whether cysts on the pancreas will develop into cancer or remain benign.
Read More
Bluestar Genomics Commercializes Pancreatic Cancer Test
Bluestar Genomics has announced its U.S. and international commercialization of a test for early detection of pancreatic cancer.
Read More
New Genetic Culprit Suspected of Pancreatic Cancer Onset
New research points to the inactivation of a previously unidentified gene as a likely culprit in the development of pancreatic cancer.
Read More
Bluestar Genomics’ Pancreatic Cancer Detection Test Achieves High Sensitivity & Specificity
Bluestar Genomics announced the results of a validation study for its early pancreatic cancer detection test. Â
Read More
Pancreatic Cancer Could be Diagnosed up to Three Years Earlier
Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests.
Read More
Bluestar Genomics Receives CAP Accreditation for its Clinical Lab
The CAP certification enables Bluestar to serve physicians as it works towards broad commercialization of its pancreatic cancer test.Â
Read More
PancreaSeq Molecular Test Outperforms Current Guidelines
The PancreaSeq molecular test accurately classifies pancreatic cysts as potentially cancerous or benign, a large, multi-center study found.
Read More
Personalis & BC Cancer Assess Benefits of ctDNA for Colorectal, Pancreatic Cancers
Personalis and BC Cancer will deploy a personalized liquid biopsy-based assay for a study of patients with colorectal and pancreatic cancers.
Read More